デフォルト表紙
市場調査レポート
商品コード
1291344

異常ヘモグロビン症市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測

Hemoglobinopathies Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2023-2028

出版日: | 発行: IMARC | ページ情報: 英文 143 Pages | 納期: 2~3営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=160.56円
異常ヘモグロビン症市場:世界の産業動向、シェア、規模、成長機会、2023-2028年予測
出版日: 2023年05月29日
発行: IMARC
ページ情報: 英文 143 Pages
納期: 2~3営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

世界の異常ヘモグロビン症の市場規模は、2022年に92億米ドルに達しました。今後、IMARC Groupは、2023年から2028年の間に9.39%の成長率(CAGR)を示し、2028年までに163億米ドルに達すると予測しています。

異常ヘモグロビン症は、ヘモグロビン分子の構造異常や産生異常を引き起こす遺伝性血液疾患です。鎌状赤血球、サラセミア、ヘモグロビンC、βサラセミアは、一般的なヘモグロビン症の一種です。異常ヘモグロビン症は、遺伝子検査、高速液体クロマトグラフィーによるヘモグロビン検査、日常的な赤血球数測定、ヘモグロビン等電点(Hb IEF)、ヘモグロビン電気泳動(Hb ELP)検査によって発見されます。皮膚の青白さ、息切れ、手足の冷え、疲労感、痛み、手足の腫れなどは、異常ヘモグロビン症の代表的な症状の一部です。広く使われている異常ヘモグロビン症の治療法には、抗生物質、ACE阻害剤、幹細胞移植、輸血、ヒドロキシウレア、鎮痛剤などがあります。

異常ヘモグロビン症の市場動向:

鎌状赤血球症(SCD)やサラセミアなど、さまざまな病態の有病率の増加は、市場の成長を促す重要な要因の1つとなっています。異常ヘモグロビン症は、異常なヘモグロビンが赤血球を変形・損傷させ、硬く粘着性のある状態にすることで発症します。これに伴い、特に、他の様々な慢性疾患にもかかりやすい老年人口の間で貧血の有病率が上昇していることが、市場成長に好影響を与えています。遺伝子の編集、削除、追加、変更、DNAの改変によってヘモグロビン症を治療するCRISPR-Cas9技術の開発など、さまざまな技術的進歩が市場成長に弾みをつけています。これに伴い、ヘモグロビン症の治療に遺伝子治療が広く採用されていることが、市場成長に好影響を与えています。その他の要因としては、ヘルスケア産業の大幅な拡大、手頃な価格で異常ヘモグロビン症を治療するための新規治療法を導入するための研究開発(R&D)活動を促進する様々な政府イニシアティブの実施などがあり、市場に明るい展望をもたらすと予想されています。

目次

第1章 序文

第2章 調査範囲と調査手法

  • 調査目的
  • 利害関係者
  • データソース
    • 一次情報
    • 二次情報
  • 市場推定
    • ボトムアップアプローチ
    • トップダウンアプローチ
  • 予測手法

第3章 エグゼクティブサマリー

第4章 イントロダクション

  • 概要
  • 主要な産業動向

第5章 異常ヘモグロビン症の世界市場

  • 市場概要
  • 市場実績
  • COVID-19のインパクト
  • 市場予測

第6章 タイプ別市場内訳

  • サラセミア
    • 市場動向
    • 主要セグメント
      • アルファ型サラセミア
      • ベータ型サラセミア
    • 市場予測
  • 鎌状赤血球症
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第7章 治療法別市場内訳

  • 輸血
    • 市場動向
    • 市場予測
  • 幹細胞移植
    • 市場動向
    • 市場予測
  • 鎮痛剤
    • 市場動向
    • 市場予測
  • 抗生物質
    • 市場動向
    • 市場予測
  • ACEインヒビター
    • 市場動向
    • 市場予測
  • ヒドロキシ尿素
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第8章 検査タイプ別市場内訳

  • 赤血球(RBC)数
    • 市場動向
    • 市場予測
  • 遺伝子検査
    • 市場動向
    • 市場予測
  • 高性能液体クロマトグラフィー(HPLC)
    • 市場動向
    • 市場予測
  • ヘモグロビン等電点集束法(Hb IEF)
    • 市場動向
    • 市場予測
  • ヘモグロビン電気泳動法(Hb ELP)
    • 市場動向
    • 市場予測
  • ヘモグロビン溶解度試験
    • 市場動向
    • 市場予測

第9章 エンドユーザー別市場内訳

  • 病院・診療所
    • 市場動向
    • 市場予測
  • 診断ラボラトリー
    • 市場動向
    • 市場予測
  • その他
    • 市場動向
    • 市場予測

第10章 地域別市場内訳

  • 北米
    • 米国
      • 市場動向
      • 市場予測
    • カナダ
      • 市場動向
      • 市場予測
  • アジア太平洋地域
    • 中国
      • 市場動向
      • 市場予測
    • 日本
      • 市場動向
      • 市場予測
    • インド
      • 市場動向
      • 市場予測
    • 韓国
      • 市場動向
      • 市場予測
    • オーストラリア
      • 市場動向
      • 市場予測
    • インドネシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 欧州
    • ドイツ
      • 市場動向
      • 市場予測
    • フランス
      • 市場動向
      • 市場予測
    • 英国
      • 市場動向
      • 市場予測
    • イタリア
      • 市場動向
      • 市場予測
    • スペイン
      • 市場動向
      • 市場予測
    • ロシア
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • ラテンアメリカ
    • ブラジル
      • 市場動向
      • 市場予測
    • メキシコ
      • 市場動向
      • 市場予測
    • その他
      • 市場動向
      • 市場予測
  • 中東・アフリカ地域
    • 市場動向
    • 国別市場内訳
    • 市場展望

第11章 SWOT分析

  • 概要
  • 強み
  • 弱み
  • 機会(Opportunities
  • 脅威(Treats

第12章 バリューチェーン分析

第13章 ポーターのファイブフォース分析

  • 概要
  • 買い手の交渉力
  • 供給企業の交渉力
  • 競合の度合い
  • 新規参入業者の脅威
  • 代替品の脅威

第14章 価格分析

第15章 競合情勢

  • 市場構造
  • 主要企業
  • 主要企業のプロファイル
    • Bio-Rad Laboratories Inc.
    • bluebird bio Inc.
    • Bristol-Myers Squibb Company
    • Danaher Corporation
    • Emmaus Life Sciences Inc.
    • Gamida-Cell Ltd.
    • Global Blood Therapeutics Inc.
    • Novartis AG
    • PerkinElmer Inc.
    • Pfizer Inc.
    • Prolong Pharmaceuticals LLC
    • Sangamo Therapeutics Inc.
    • Sysmex Corporation
図表

List of Figures

  • Figure 1: Global: Hemoglobinopathies Market: Major Drivers and Challenges
  • Figure 2: Global: Hemoglobinopathies Market: Sales Value (in Billion US$), 2017-2022
  • Figure 3: Global: Hemoglobinopathies Market Forecast: Sales Value (in Billion US$), 2023-2028
  • Figure 4: Global: Hemoglobinopathies Market: Breakup by Type (in %), 2022
  • Figure 5: Global: Hemoglobinopathies Market: Breakup by Treatment (in %), 2022
  • Figure 6: Global: Hemoglobinopathies Market: Breakup by Test Type (in %), 2022
  • Figure 7: Global: Hemoglobinopathies Market: Breakup by End User (in %), 2022
  • Figure 8: Global: Hemoglobinopathies Market: Breakup by Region (in %), 2022
  • Figure 9: Global: Hemoglobinopathies (Thalassemia) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 10: Global: Hemoglobinopathies (Thalassemia) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 11: Global: Hemoglobinopathies (Sickle Cell Disease) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 12: Global: Hemoglobinopathies (Sickle Cell Disease) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 13: Global: Hemoglobinopathies (Other Types) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 14: Global: Hemoglobinopathies (Other Types) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 15: Global: Hemoglobinopathies (Blood Transfusion) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 16: Global: Hemoglobinopathies (Blood Transfusion) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 17: Global: Hemoglobinopathies (Stem-cell Transplantation) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 18: Global: Hemoglobinopathies (Stem-cell Transplantation) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 19: Global: Hemoglobinopathies (Analgesics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 20: Global: Hemoglobinopathies (Analgesics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 21: Global: Hemoglobinopathies (Antibiotics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 22: Global: Hemoglobinopathies (Antibiotics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 23: Global: Hemoglobinopathies (ACE Inhibitors) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 24: Global: Hemoglobinopathies (ACE Inhibitors) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 25: Global: Hemoglobinopathies (Hydroxyurea) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 26: Global: Hemoglobinopathies (Hydroxyurea) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 27: Global: Hemoglobinopathies (Other Treatments) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 28: Global: Hemoglobinopathies (Other Treatments) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 29: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 30: Global: Hemoglobinopathies (Red Blood Cell (RBC) Count) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 31: Global: Hemoglobinopathies (Genetic Testing) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 32: Global: Hemoglobinopathies (Genetic Testing) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 33: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 34: Global: Hemoglobinopathies (High Performance Liquid Chromatography-HPLC) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 35: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 36: Global: Hemoglobinopathies (Hemoglobin Isoelectric Focusing-Hb IEF) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 37: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 38: Global: Hemoglobinopathies (Hemoglobin Electrophoresis-Hb ELP) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 39: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 40: Global: Hemoglobinopathies (Hemoglobin Solubility Test) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 41: Global: Hemoglobinopathies (Hospitals and Clinics) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 42: Global: Hemoglobinopathies (Hospitals and Clinics) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 43: Global: Hemoglobinopathies (Diagnostics Laboratories) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 44: Global: Hemoglobinopathies (Diagnostics Laboratories) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 45: Global: Hemoglobinopathies (Other End Users) Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 46: Global: Hemoglobinopathies (Other End Users) Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 47: North America: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 48: North America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 49: United States: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 50: United States: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 51: Canada: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 52: Canada: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 53: Asia-Pacific: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 54: Asia-Pacific: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 55: China: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 56: China: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 57: Japan: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 58: Japan: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 59: India: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 60: India: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 61: South Korea: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 62: South Korea: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 63: Australia: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 64: Australia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 65: Indonesia: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 66: Indonesia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 67: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 68: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 69: Europe: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 70: Europe: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 71: Germany: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 72: Germany: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 73: France: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 74: France: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 75: United Kingdom: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 76: United Kingdom: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 77: Italy: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 78: Italy: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 79: Spain: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 80: Spain: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 81: Russia: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 82: Russia: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 83: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 84: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 85: Latin America: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 86: Latin America: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 87: Brazil: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 88: Brazil: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 89: Mexico: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 90: Mexico: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 91: Others: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 92: Others: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 93: Middle East and Africa: Hemoglobinopathies Market: Sales Value (in Million US$), 2017 & 2022
  • Figure 94: Middle East and Africa: Hemoglobinopathies Market: Breakup by Country (in %), 2022
  • Figure 95: Middle East and Africa: Hemoglobinopathies Market Forecast: Sales Value (in Million US$), 2023-2028
  • Figure 96: Global: Hemoglobinopathies Industry: SWOT Analysis
  • Figure 97: Global: Hemoglobinopathies Industry: Value Chain Analysis
  • Figure 98: Global: Hemoglobinopathies Industry: Porter's Five Forces Analysis

List of Tables

  • Table 1: Global: Hemoglobinopathies Market: Key Industry Highlights, 2022 and 2028
  • Table 2: Global: Hemoglobinopathies Market Forecast: Breakup by Type (in Million US$), 2023-2028
  • Table 3: Global: Hemoglobinopathies Market Forecast: Breakup by Treatment (in Million US$), 2023-2028
  • Table 4: Global: Hemoglobinopathies Market Forecast: Breakup by Test Type (in Million US$), 2023-2028
  • Table 5: Global: Hemoglobinopathies Market Forecast: Breakup by End User (in Million US$), 2023-2028
  • Table 6: Global: Hemoglobinopathies Market Forecast: Breakup by Region (in Million US$), 2023-2028
  • Table 7: Global: Hemoglobinopathies Market: Competitive Structure
  • Table 8: Global: Hemoglobinopathies Market: Key Players
目次
Product Code: SR112023A5123

The global hemoglobinopathies market size reached US$ 9.2 Billion in 2022. Looking forward, IMARC Group expects the market to reach US$ 16.3 Billion by 2028, exhibiting a growth rate (CAGR) of 9.39% during 2023-2028.

Hemoglobinopathies is genetic blood disorder that causes structural and production abnormalities in hemoglobin molecules. Sickle cell, thalassemia, hemoglobin C, and beta-thalassemia are some of the common types of hemoglobinopathies. Hemoglobinopathies are detected by genetic testing, hemoglobin by high-performance liquid chromatography, routine red blood cell (RBC) count, hemoglobin isoelectric focusing (Hb IEF), and hemoglobin electrophoresis (Hb ELP) test. Pale skin, shortness of breath, cold hands or feet, tiredness, pain, and swelling in the hands and feet are a few of the most common symptoms hemoglobinopathies. Some of the widely used hemoglobinopathies treatment solutions include antibiotics, ACE inhibitors, stem-cell transplantation, blood transfusions, hydroxyurea, and analgesic.

Hemoglobinopathies Market Trends:

The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Breakup by Treatment:

Hemoglobinopathies Market Trends:

The increasing prevalence of various medical conditions, such as sickle cell disease (SCD) and thalassemia, is one of the key factors driving the growth of the market. Hemoglobinopathies are caused by abnormal hemoglobin that deforms and damages red blood cells and makes them hard and sticky. In line with this, the rising prevalence of anemia, especially among the geriatric population, which is also susceptible to various other chronic ailments, is favoring the market growth. Various technological advancements, such as the development of CRISPR-Cas9 technology to cure hemoglobinopathies by editing, removing, adding, or altering genes and modifying the DNA, are providing an impetus to the market growth. In line with this, the widespread adoption of gene therapy for the treatment of hemoglobinopathy is favoring market growth. Other factors, such as the significant expansion in the healthcare industry, along with the implementation of various government initiatives to promote research and development (R&D) activities to introduce novel therapies for treating hemoglobinopathies at affordable costs is anticipated to provide a positive outlook for the market.

Key Market Segmentation:

IMARC Group provides an analysis of the key trends in each sub-segment of the global hemoglobinopathies market report, along with forecasts at the global, regional and country level from 2023-2028. Our report has categorized the market based on type, treatment, test type and end user.

Breakup by Type:

Thalassemia

Alpha Thalassemia

Beta Thalassemia

Sickle Cell Disease

Others

Breakup by Treatment:

Blood Transfusion

Stem-cell Transplantation

Analgesics

Antibiotics

ACE Inhibitors

Hydroxyurea

Others

Breakup by Test Type:

Red Blood Cell (RBC) Count

Genetic Testing

High Performance Liquid Chromatography (HPLC)

Hemoglobin Isoelectric Focusing (Hb IEF)

Hemoglobin Electrophoresis (Hb ELP)

Hemoglobin Solubility Test

Breakup by End User:

Hospitals and Clinics

Diagnostics Laboratories

Others

Breakup by Region:

North America

United States

Canada

Asia-Pacific

China

Japan

India

South Korea

Australia

Indonesia

Others

Europe

Germany

France

United Kingdom

Italy

Spain

Russia

Others

Latin America

Brazil

Mexico

Others

Middle East and Africa

Competitive Landscape:

The competitive landscape of the industry has also been examined along with the profiles of the key players being Bio-Rad Laboratories Inc., bluebird bio Inc., Bristol-Myers Squibb Company, Danaher Corporation, Emmaus Life Sciences Inc., Gamida-Cell Ltd., Global Blood Therapeutics Inc., Novartis AG, PerkinElmer Inc., Pfizer Inc., Prolong Pharmaceuticals LLC, Sangamo Therapeutics Inc. and Sysmex Corporation.

Key Questions Answered in This Report

1. What was the size of the global hemoglobinopathies market in 2022?

2. What is the expected growth rate of the global hemoglobinopathies market during 2023-2028?

3. What has been the impact of COVID-19 on the global hemoglobinopathies market?

4. What are the key factors driving the global hemoglobinopathies market?

5. What is the breakup of the global hemoglobinopathies market based on the type?

6. What is the breakup of the global hemoglobinopathies market based on the treatment?

7. What are the key regions in the global hemoglobinopathies market?

8. Who are the key players/companies in the global hemoglobinopathies market?

Table of Contents

1   Preface

2   Scope and Methodology

  • 2.1  Objectives of the Study
  • 2.2  Stakeholders
  • 2.3  Data Sources
    • 2.3.1  Primary Sources
    • 2.3.2  Secondary Sources
  • 2.4  Market Estimation
    • 2.4.1  Bottom-Up Approach
    • 2.4.2  Top-Down Approach
  • 2.5  Forecasting Methodology

3   Executive Summary

4   Introduction

  • 4.1  Overview
  • 4.2  Key Industry Trends

5   Global Hemoglobinopathies Market

  • 5.1  Market Overview
  • 5.2  Market Performance
  • 5.3  Impact of COVID-19
  • 5.4  Market Forecast

6   Market Breakup by Type

  • 6.1  Thalassemia
    • 6.1.1 Market Trends
    • 6.1.2 Key Segments
      • 6.1.2.1 Alpha Thalassemia
      • 6.1.2.2 Beta Thalassemia
    • 6.1.3 Market Forecast
  • 6.2  Sickle Cell Disease
    • 6.2.1 Market Trends
    • 6.2.2 Market Forecast
  • 6.3  Others
    • 6.3.1 Market Trends
    • 6.3.2 Market Forecast

7   Market Breakup by Treatment

  • 7.1  Blood Transfusion
    • 7.1.1 Market Trends
    • 7.1.2 Market Forecast
  • 7.2  Stem-cell Transplantation
    • 7.2.1 Market Trends
    • 7.2.2 Market Forecast
  • 7.3  Analgesics
    • 7.3.1 Market Trends
    • 7.3.2 Market Forecast
  • 7.4  Antibiotics
    • 7.4.1 Market Trends
    • 7.4.2 Market Forecast
  • 7.5  ACE Inhibitors
    • 7.5.1 Market Trends
    • 7.5.2 Market Forecast
  • 7.6  Hydroxyurea
    • 7.6.1 Market Trends
    • 7.6.2 Market Forecast
  • 7.7  Others
    • 7.7.1 Market Trends
    • 7.7.2 Market Forecast

8   Market Breakup by Test Type

  • 8.1  Red Blood Cell (RBC) Count
    • 8.1.1 Market Trends
    • 8.1.2 Market Forecast
  • 8.2  Genetic Testing
    • 8.2.1 Market Trends
    • 8.2.2 Market Forecast
  • 8.3  High Performance Liquid Chromatography (HPLC)
    • 8.3.1 Market Trends
    • 8.3.2 Market Forecast
  • 8.4  Hemoglobin Isoelectric Focusing (Hb IEF)
    • 8.4.1 Market Trends
    • 8.4.2 Market Forecast
  • 8.5  Hemoglobin Electrophoresis (Hb ELP)
    • 8.5.1 Market Trends
    • 8.5.2 Market Forecast
  • 8.6  Hemoglobin Solubility Test
    • 8.6.1 Market Trends
    • 8.6.2 Market Forecast

9   Market Breakup by End User

  • 9.1  Hospitals and Clinics
    • 9.1.1 Market Trends
    • 9.1.2 Market Forecast
  • 9.2  Diagnostics Laboratories
    • 9.2.1 Market Trends
    • 9.2.2 Market Forecast
  • 9.3  Others
    • 9.3.1 Market Trends
    • 9.3.2 Market Forecast

10  Market Breakup by Region

  • 10.1  North America
    • 10.1.1 United States
      • 10.1.1.1 Market Trends
      • 10.1.1.2 Market Forecast
    • 10.1.2 Canada
      • 10.1.2.1 Market Trends
      • 10.1.2.2 Market Forecast
  • 10.2  Asia-Pacific
    • 10.2.1 China
      • 10.2.1.1 Market Trends
      • 10.2.1.2 Market Forecast
    • 10.2.2 Japan
      • 10.2.2.1 Market Trends
      • 10.2.2.2 Market Forecast
    • 10.2.3 India
      • 10.2.3.1 Market Trends
      • 10.2.3.2 Market Forecast
    • 10.2.4 South Korea
      • 10.2.4.1 Market Trends
      • 10.2.4.2 Market Forecast
    • 10.2.5 Australia
      • 10.2.5.1 Market Trends
      • 10.2.5.2 Market Forecast
    • 10.2.6 Indonesia
      • 10.2.6.1 Market Trends
      • 10.2.6.2 Market Forecast
    • 10.2.7 Others
      • 10.2.7.1 Market Trends
      • 10.2.7.2 Market Forecast
  • 10.3  Europe
    • 10.3.1 Germany
      • 10.3.1.1 Market Trends
      • 10.3.1.2 Market Forecast
    • 10.3.2 France
      • 10.3.2.1 Market Trends
      • 10.3.2.2 Market Forecast
    • 10.3.3 United Kingdom
      • 10.3.3.1 Market Trends
      • 10.3.3.2 Market Forecast
    • 10.3.4 Italy
      • 10.3.4.1 Market Trends
      • 10.3.4.2 Market Forecast
    • 10.3.5 Spain
      • 10.3.5.1 Market Trends
      • 10.3.5.2 Market Forecast
    • 10.3.6 Russia
      • 10.3.6.1 Market Trends
      • 10.3.6.2 Market Forecast
    • 10.3.7 Others
      • 10.3.7.1 Market Trends
      • 10.3.7.2 Market Forecast
  • 10.4  Latin America
    • 10.4.1 Brazil
      • 10.4.1.1 Market Trends
      • 10.4.1.2 Market Forecast
    • 10.4.2 Mexico
      • 10.4.2.1 Market Trends
      • 10.4.2.2 Market Forecast
    • 10.4.3 Others
      • 10.4.3.1 Market Trends
      • 10.4.3.2 Market Forecast
  • 10.5  Middle East and Africa
    • 10.5.1 Market Trends
    • 10.5.2 Market Breakup by Country
    • 10.5.3 Market Forecast

11  SWOT Analysis

  • 11.1  Overview
  • 11.2  Strengths
  • 11.3  Weaknesses
  • 11.4  Opportunities
  • 11.5  Threats

12  Value Chain Analysis

13  Porters Five Forces Analysis

  • 13.1  Overview
  • 13.2  Bargaining Power of Buyers
  • 13.3  Bargaining Power of Suppliers
  • 13.4  Degree of Competition
  • 13.5  Threat of New Entrants
  • 13.6  Threat of Substitutes

14  Price Analysis

15  Competitive Landscape

  • 15.1  Market Structure
  • 15.2  Key Players
  • 15.3  Profiles of Key Players
    • 15.3.1  Bio-Rad Laboratories Inc.
      • 15.3.1.1 Company Overview
      • 15.3.1.2 Product Portfolio
      • 15.3.1.3 Financials
      • 15.3.1.4 SWOT Analysis
    • 15.3.2  bluebird bio Inc.
      • 15.3.2.1 Company Overview
      • 15.3.2.2 Product Portfolio
      • 15.3.2.3 Financials
      • 15.3.2.4 SWOT Analysis
    • 15.3.3  Bristol-Myers Squibb Company
      • 15.3.3.1 Company Overview
      • 15.3.3.2 Product Portfolio
      • 15.3.3.3 Financials
      • 15.3.3.4 SWOT Analysis
    • 15.3.4  Danaher Corporation
      • 15.3.4.1 Company Overview
      • 15.3.4.2 Product Portfolio
      • 15.3.4.3 Financials
      • 15.3.4.4 SWOT Analysis
    • 15.3.5  Emmaus Life Sciences Inc.
      • 15.3.5.1 Company Overview
      • 15.3.5.2 Product Portfolio
      • 15.3.5.3 Financials
    • 15.3.6  Gamida-Cell Ltd.
      • 15.3.6.1 Company Overview
      • 15.3.6.2 Product Portfolio
      • 15.3.6.3 Financials
    • 15.3.7  Global Blood Therapeutics Inc.
      • 15.3.7.1 Company Overview
      • 15.3.7.2 Product Portfolio
      • 15.3.7.3 Financials
    • 15.3.8  Novartis AG
      • 15.3.8.1 Company Overview
      • 15.3.8.2 Product Portfolio
      • 15.3.8.3 Financials
      • 15.3.8.4 SWOT Analysis
    • 15.3.9  PerkinElmer Inc.
      • 15.3.9.1 Company Overview
      • 15.3.9.2 Product Portfolio
      • 15.3.9.3 Financials
      • 15.3.9.4 SWOT Analysis
    • 15.3.10  Pfizer Inc.
      • 15.3.10.1 Company Overview
      • 15.3.10.2 Product Portfolio
      • 15.3.10.3 Financials
      • 15.3.10.4 SWOT Analysis
    • 15.3.11  Prolong Pharmaceuticals LLC
      • 15.3.11.1 Company Overview
      • 15.3.11.2 Product Portfolio
    • 15.3.12  Sangamo Therapeutics Inc.
      • 15.3.12.1 Company Overview
      • 15.3.12.2 Product Portfolio
      • 15.3.12.3 Financials
      • 15.3.12.4 SWOT Analysis
    • 15.3.13  Sysmex Corporation
      • 15.3.13.1 Company Overview
      • 15.3.13.2 Product Portfolio
      • 15.3.13.3 Financials
      • 15.3.13.4 SWOT Analysis